Organic Active Ingredients TRIZ Cases

Isotopic substitution of hydrogen with deuterium in psilocybin extends metabolic stability while enabling legal detection via unique signatures.

Nanostructured cellulose prevents agglomeration of nanosized pharmaceutical particles, improving dissolution rate and bioavailability.

Organozinc coupling synthesizes SGLT2 inhibitors to control blood glucose without side effects from conventional agents.

Combining ipatasertib, atezolizumab, and taxane targets metastatic triple-negative breast cancer through synergistic pathway inhibition.

Thiocarbamate inhibitors combined with lipid carriers resolve low aqueous solubility, enabling effective oral dosing for cancer treatment.

Applying eugenol emulgel softens cured resin, lowering debonding force and preventing enamel damage during orthodontic treatment.

Targeting CD105-expressing fibroblasts with antagonists reduces tumor vascularity and overcomes resistance in castration-resistant prostate cancer.

Novel fused bicyclic heteroaromatic compounds act as potent RAF kinase inhibitors.

Multiblock poly(sarcosine) copolymers self-assemble into micelles to encapsulate hydrophobic drugs in aqueous solutions.

Adjusting rilpivirine dosage to 25 mg daily suppresses HIV viral load in children while minimizing adverse drug reactions.

Formula I compounds inhibit GSK-3 to reduce neuronal toxicity and neuroinflammation in Alzheimer's disease.

A pharmaceutical composition combining forskolin and retinoic acid protects auditory cells from cisplatin-induced damage.

Formula I urea compounds inhibit the SGLT1 transporter, reducing intestinal glucose absorption and lowering blood sugar levels in diabetic models.

Non-nutritive sugars form water-soluble complexes with poorly soluble erectile dysfunction drugs, resolving delayed onset and inconsistent bioavailability.

Intranasal salvinorin A delivery bypasses hepatic metabolism to improve bioavailability while avoiding manic side effects from 5HT2A receptor activity.

Pre-mixed ascorbic acid formulations eliminate dilution steps by using stabilizing agents to maintain room temperature stability.

Compounds inhibit triple mutant EGFR variants, overcoming resistance to osimertinib while reducing on-target toxicities.

VMAT2 inhibitors modulate monoamine transport to reduce symptom severity while minimizing off-target side effects in mood disorders.

Antibody-IR700 conjugates target cancer cells to induce selective necrosis via near-infrared light, reducing harm to normal tissues.

Cyclosporin acts as an intermediary to prevent nasolacrimal stenosis and keratoconjunctivitis during chemotherapy.

Liposomal formulations deliver chemotherapeutic agents directly into the peritoneal cavity to enhance drug penetration and patient tolerability.

Indazole derivatives inhibit fungal cytochrome b and Hsp90 to overcome fluconazole resistance in Candida albicans.

Segmenting the core structure from sugar modules resolves the contradiction between low water solubility and high antitumor activity in curcumin derivatives.

Compound Ia inhibits BRAF dimers to overcome resistance and relapse in brain metastatic melanoma patients.

5-Alkynyl-pyridine compounds inhibit PI3Kalpha activity, resolving the lack of effective pathway inhibitors in cancer treatment.

Silver nitrate substitution reaction converts cyanocobalamin to hydroxocobalamin hydrochloride in a water-methanol solvent system.

Combining sarilumab with DMARDs targets the IL-6R pathway to inhibit structural damage progression in rheumatoid arthritis patients.

Dietary fibres modulate neuroendocrine responses to alleviate gastrointestinal discomfort in medical nutrition products.

A continuous Z-value metric classifies pediatric septic shock patients using gene expression mosaics.

Pyrazole and imidazole derivatives selectively inhibit orexin receptors, addressing the inability of current treatments to target CNS dysfunctions.

Selective compounds detect TDP43 aggregates across the blood-brain barrier, resolving the bottleneck of insensitive diagnosis in ALS and FTD.

A thermosensitive liposome formulation uses a bilayer containing at least 15% DPPG2 to control drug release.

Targeting the MAPK signaling pathway with RAF, ERK1/2, and MEK1/2 inhibitors prevents hearing threshold shifts caused by cisplatin chemotherapy.

Antibody drug conjugate targets IL-13Rα2-expressing cancer cells using a pyrrolobenzodiazepine warhead to reduce recurrence in glioblastoma.

E3 ligase-binding moieties bridge BTK to ubiquitin complexes, enabling proteasomal degradation that bypasses C481S mutation resistance.

Polyvinyl alcohol hydrogel compositions retain moisture to sustain chlorhexidine release at oral tissues.

15dPGJ2-EA induces endoplasmic reticulum stress in virus-infected cells, reducing wart size while sparing healthy tissue from non-selective toxicity.

PTC299 targets both viral replication and immune response to reduce cytokine storms in COVID-19 treatment.

Replacing mannitol with lactose or trehalose prevents vial breaking and water release, ensuring copanlisib stability at pH levels above 5.5.

A bivalent metal salen complex traps free radicals through coordination bonding to maintain product stability.

Replacing mouse-derived SINE elements with human IRES sequences in a trans-acting molecule eliminates retrotransposition risks while boosting protein synthesis.

Liposome encapsulation delivers Toll-like receptor inhibitor prodrugs directly to tumor sites.

Hot-melt granulation disperses agomelatine within cross-linked polyvinylpolypyrrolidone pores to create a stable amorphous solid dispersion.

Developing a synthesis process for an IDO inhibitor with modified chemical structures to enhance tryptophan levels and anti-tumor responses.

Novel heterocyclic compounds inhibit PAS kinase activity to modulate glycogen synthesis and cellular metabolism.

Formula I compounds act as opioid receptor modulators to lower ghrelin levels, mitigating weight gain from atypical antipsychotics.

Radial cylinder chambers and axial pump cover segments recirculate drain oil through connection grooves, reducing overall transmission size.

Fused pyrimidine compounds inhibit mutant EGFR and HER2 kinases, overcoming low potency of current kinase inhibitors in lung cancer treatment.